Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Atherosclerotic Cardiovascular Disease Risk and Statin Prescription Status in Korean Adult Patients

국내 성인환자에서 죽상동맥경화성 심혈관질환 위험도와 스타틴 처방 현황

  • Kim, Jong Yoon (College of Pharmacy, Dongduk Women's University) ;
  • Rhew, Kiyon (College of Pharmacy, Dongduk Women's University)
  • 김종윤 (동덕여자대학교 약학대학) ;
  • 유기연 (동덕여자대학교 약학대학)
  • Received : 2021.06.04
  • Accepted : 2021.08.06
  • Published : 2021.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Cardiovascular (CV) disease is known as one of the major causes of death from disease worldwide. Statin therapy plays a pivotal role in atherosclerotic cardiovascular disease (ASCVD) lowering the LDL-cholesterol level effectively. The purpose of this study was to evaluate the association of the intensity of statin therapy in adult patients of Korea and the risk of ASCVD of the patient group. Methods: We used data from sample of patients from the Health Insurance Review and Assessment Service (HIRA-NPS-2018). We analyzed the patterns of prescribing statins including types of statin, statin intensity, and number of patients with ASCVD or risk of ASCVD. Results: 155,512 patients were included in the analysis, and 27,950 patients (18.0%) was over 75 years. High-intensity statin usage was increased in ASCVD patients compared with the low-intensity statin use. The OR (odds ratio) of high-intensity statin were increased in myocardial infarction patients compared with low-intensity statin use showing the highest OR; 12.40 (95% CI; 9.48-16.22). At patient groups of angina, ischemic heart disease and carotid disease, high-intensity statin prescription rate was increased compared with low-intensity statin. However, there was no statistical significance between both statin prescription rates in patients of peripheral arterial disease, abdominal aneurysm, diabetic mellitus and atherosclerosis. Conclusion: The statin prescription rate showed intensity increasing tendency according to the risk of ASCVD. More aggressive statin therapy might be beneficial for the ASCVD patients based on the recent guidelines of dyslipidemia.

Keywords

Acknowledgement

이 논문은 2019년도 동덕여자대학교 연구비 지원에 의하여 수행된 것으로 이에 감사드립니다.

References

  1. Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 2015;132(17):1667-78. https://doi.org/10.1161/CIRCULATIONAHA.114.008720
  2. de Fatima Marinho de Souza M, Gawryszewski VP, Ordunez P, Sanhueza A, Espinal MA. Cardiovascular disease mortality in the americas: Current trends and disparities. Heart 2012;98(16):1207-12. https://doi.org/10.1136/heartjnl-2012-301828
  3. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: A report from the american heart association. Circulation 2019;139(10):e56-e528.
  4. Jee SH, Jang Y, Oh DJ, et al. A coronary heart disease prediction model: the Korean Heart Study. BMJ open 2014;4(5):e005025. https://doi.org/10.1136/bmjopen-2014-005025
  5. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: A systematic review. JAMA 2005;294(17):2203-9. https://doi.org/10.1001/jama.294.17.2203
  6. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US preventive services task force. JAMA 2016;316(19):2008-2024. https://doi.org/10.1001/jama.2015.15629
  7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333(20):1301-1307. https://doi.org/10.1056/NEJM199511163332001
  8. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292(5519):1160-4. https://doi.org/10.1126/science.1059344
  9. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;92(2):152-60. https://doi.org/10.1016/S0002-9149(03)00530-7
  10. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81(5):582-7. https://doi.org/10.1016/s0002-9149(97)00965-x
  11. Rhee E, Kim HC, Kim JH, et al. 2018 guidelines for the management of dyslipidemia in Korea. Journal of Lipid and Atherosclerosis. 2019;8(2):78-131. https://doi.org/10.12997/jla.2019.8.2.78
  12. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary. Endocr Pract 2018;24(1):91-120. https://doi.org/10.4158/cs-2017-0153
  13. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):111-88. https://doi.org/10.1093/eurheartj/ehz455
  14. Son KB, Bae S. Patterns of statin utilisation for new users and market dynamics in South Korea: A 13-year retrospective cohort study. BMJ open 2019;9(3):e026603. https://doi.org/10.1136/bmjopen-2018-026603
  15. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37(39):2999-3058. https://doi.org/10.1093/eurheartj/ehw272
  16. Kim S, Han S, Rane PP, Qian Y, Zhao Z, Suh HS. Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea. PLoS One 2020;15(1):e0228472. https://doi.org/10.1371/journal.pone.0228472
  17. Kwon JE, Kim Y, Hyun S, et al. Cholesterol lowering effects of low-dose statins in Korean patients. J lipid Atheroscler 2014;3(1):21-28. https://doi.org/10.12997/jla.2014.3.1.21
  18. Naito R, Miyauchi K, Daida H. Racial differences in the cholesterollowering effect of statin. J Atheroscler Thromb 2017;24(1):19-25. https://doi.org/10.5551/jat.RV16004
  19. Korea Centers for Disease Control & Prevention. Chronic disease status and issues 2019. Available from:http://nih.go.kr/gallery.es?mid=a20503020000&bid=0003&b_list=9&act=view&list_no=144581&nPage=1&vlist_no_npage=2&keyField=&keyWord=&orderby=. Accessed May 01, 2021.
  20. Kim HJ, Kim Y, Cho Y, Jun B, Oh KW. Trends in the prevalence of major cardiovascular disease risk factors among Korean adults: Results from the Korea National Health and Nutrition Examination Survey, 1998-2012. Int J Cardiol 2014;174(1):64-72. https://doi.org/10.1016/j.ijcard.2014.03.163